Fryns-Aftimos syndrome

From WikiMD's WELLNESSPEDIA


Fryns-Aftimos syndrome
Synonyms
Pronounce N/A
Specialty N/A
Symptoms Congenital diaphragmatic hernia, craniofacial dysmorphism, limb anomalies, genitourinary abnormalities
Complications
Onset Prenatal
Duration
Types
Causes Genetic mutation
Risks
Diagnosis Clinical examination, genetic testing
Differential diagnosis Fryns syndrome, Pallister-Killian syndrome
Prevention
Treatment Supportive care, surgical intervention
Medication
Prognosis
Frequency Rare disease
Deaths


Fryns-Aftimos syndrome is a rare genetic disorder characterized by a combination of congenital anomalies. It was first described by Jean-Pierre Fryns and B. Aftimos in the medical literature. The syndrome is primarily identified by distinctive facial features, diaphragmatic hernia, and other systemic abnormalities.

Clinical Features[edit]

Individuals with Fryns-Aftimos syndrome typically present with a range of clinical features, including:

Genetics[edit]

The exact genetic cause of Fryns-Aftimos syndrome is not well understood. It is believed to follow an autosomal recessive inheritance pattern, meaning that two copies of the mutated gene, one from each parent, are required for an individual to be affected.

Diagnosis[edit]

Diagnosis of Fryns-Aftimos syndrome is primarily based on clinical evaluation and the identification of characteristic features. Prenatal diagnosis may be possible through ultrasound imaging, which can detect diaphragmatic hernia and other anomalies.

Management[edit]

There is no cure for Fryns-Aftimos syndrome, and treatment is symptomatic and supportive. Management may involve:

  • Surgical repair of diaphragmatic hernia
  • Cardiac surgery for congenital heart defects
  • Supportive therapies for feeding difficulties and respiratory issues
  • Regular monitoring and management of renal function

Prognosis[edit]

The prognosis for individuals with Fryns-Aftimos syndrome varies depending on the severity of the congenital anomalies. Early diagnosis and intervention can improve outcomes, but the condition is often associated with significant morbidity and mortality.

Related Pages[edit]

See Also[edit]

References[edit]

External Links[edit]

-

This article is a stub related to genetics. You can help WikiMD by expanding it!


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.